Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Videos|May 23, 2022
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Author(s)Grace Halsey
Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.
Advertisement
Diabetes technology - it's a jungle out there for clinicians who aren't familiar with the myriad devices and features or who have some experience with one particular system for a few patients but want to know more about others available and how they compare. Even for clinicians who have experience with a range of devices and types, an unbranded, unabiased tool for quick comparison would be helpful.
These are the "user groups" Stanford University's Korey Hood, PhD and team had in mind when they designed DiabetesWise Pro, a new one-stop diabetes device comparison tool launched in April. Hood spoke with PatientCare Online recently about the knowledge gaps and range of comfort levels he and his team identified among clinicians when it comes to recommending diabetes technology.
He describes the needs they found and the DiabetesWise Pro solution in this excerpt from our interview.
For more of Patient Care's conversation wtih Dr Hood, see:
Korey Hood, PhD, is a professor of pediatric endocrinology and of psychiatry and behavrioal sciences at Stanford Univesity, Stanford, CA. Hood also directs NIH- and foundation-funded clinical research focused on health and quality of life outcomes for persons living with diabetes. He has lived with type 1 diabetes since he was a young adult.
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement